Pfizer (PFE)
(Delayed Data from NYSE)
$29.50 USD
+0.40 (1.37%)
Updated Jul 16, 2024 04:01 PM ET
After-Market: $29.49 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.50 USD
+0.40 (1.37%)
Updated Jul 16, 2024 04:01 PM ET
After-Market: $29.49 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
by Zacks Equity Research
Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.
Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug
by Zacks Equity Research
Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.
5 Top Performing S&P 500 Stocks of November
by Tirthankar Chakraborty
President-elect Donald Trump has proposed a raft of fiscal-stimulus measures, which has pushed the S&P 500 to almost an all-time high in November
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
by Zacks Equity Research
Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.
Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
by Zacks Equity Research
Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.
J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
by Zacks Equity Research
Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.
The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental
Stock Market News for November 21, 2016
by Zacks Equity Research
Rising rate hike possibilities boosted the dollar to its best settlement in 13 years, which in turn dragged the benchmarks into the red on Friday.
Stock Market News for November 08, 2016
by Zacks Equity Research
Benchmarks ended higher on Monday after the FBI said that it would not press criminal charges against Democratic nominee Hillary Clinton
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies
Fed Meets, Q3 Earnings Continue, Election Uncertainty Rules
by Mark Vickery
With the omnipresent General Election looming, little else matters to investors at this point.
Stock Market News for October 19, 2016
by Zacks Equity Research
Upbeat earnings results led the benchmarks to close in the green on Tuesday
Market News Over Summer Vacation: PFE, AZN, TSLA, LZB
by Mark Vickery
You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.
M&A Boosts Intersil, Syngenta and Medivation in Pre-Market
by Mark Vickery
We???re seeing big gains among smaller companies ready to be purchased by much bigger fish: PFE, MDVN, SYT, ISIL.
New Research Reports for Pfizer, Cisco & Visa
by Sheraz Mian
Today's must-read reports are for Pfizer (PFE), Cisco (CSCO) and Visa (V).
Q2 Earnings Reports Come in Mixed, Futures Down Slightly
by Mark Vickery
Q2 earnings season may have passed the midway point last week, but plenty of important companies are reporting earnings this morning: PFE, PG, MNT, CVS, SODA and RCL.
Don't Make It Complicated, Own Drug Stocks
by John Blank
The basic ingredients for rising drug demand -- the frailties that accompany aging -- are going to be there for the next 2 decades, in the USA and elsewhere.
Bull of the Day: Pfizer (PFE)
by Neena Mishra
Bet on this big pharma stock for growth, stability and income.
Bear of the Day: AbbVie (ABBV)
by Kevin Cook
Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus
Stock Market News for May 04, 2016
by Zacks Equity Research
Stock Market News for April 07, 2016
by Zacks Equity Research
Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks
Stock Market News for March 22, 2012
by Zacks Equity Research
Gains in healthcare and telecom stocks helped the benchmarks end marginally higher on Monday.